Everest Medicines announced that Nefecon, the first-in-disease treatment for primary immunoglobulin A nephropathy, has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary.
Everest Medicines announced that Nefecon, the first-in-disease treatment for primary immunoglobulin A nephropathy, has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary.